跳到主要內容

臺灣博碩士論文加值系統

(100.28.132.102) 您好!臺灣時間:2024/06/25 15:56
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:邱翰昇
研究生(外文):Chiu, Han-Sheng
論文名稱:中小企業股票初次公開發行之挑戰 : 以H生技公司為例
論文名稱(外文):The challenge of small and medium enterprise for initial public offering: a case of h biotechnology company
指導教授:吳文傑吳文傑引用關係
指導教授(外文):Wu, Jack
學位類別:碩士
校院名稱:國立政治大學
系所名稱:國際經營管理英語碩士學位學程(IMBA)
學門:商業及管理學門
學類:企業管理學類
論文種類:學術論文
論文出版年:2018
畢業學年度:106
語文別:英文
論文頁數:84
中文關鍵詞:首次公開募股中小型企業
外文關鍵詞:IPOSME
相關次數:
  • 被引用被引用:0
  • 點閱點閱:166
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
The purpose of this thesis is to check the readiness of a medium size family company, H Biotechnology Company, for initial public offering (IPO). In recent, like most of small and medium size companies, H Company faces a bottleneck to grow due to difficulties of recruiting suitable elites as well as raising money from financing channels. Moreover, it is also not an easy task for an unknown medium size company to initiate transactions with big or foreign companies that did not have any cooperation experience before; however, it is the road a medium size company must take in order to grow well. Therefore, IPO is an option that H Company must take into consideration. Starting from preparation to IPO, the company will scan itself from bottom up thoroughly and make positive changes accordingly throughout the process. Once IPO successfully, there will be more chances and resources for the company to recruit talents and grow. Through preliminary scan in this thesis, hope to point out some parts that H Company has to improve in order to IPO in the near future.
1. Executive Summary 1
1.1 Purpose 1
1.2 Small and Medium Enterprise in Taiwan 1
1.3 Capital Market in Taiwan 2
1.4 The Company 3
1.5 The Industry 3
1.6 The Competitor 4
1.7 The Customer 5
1.8 The Management 5
1.9 The Financials 6
1.10 The IPO Evaluation 6
1.11 Brief Summary 7
2. Small and Medium Enterprise in Taiwan 8
2.1 Role and Trend 8
2.2 Length of Existence 13
2.3 Distribution by Industry 15
2.4 Funding 16
2.5 Challenges 17
3. Capital Market in Taiwan 19
3.1 Capital Markets Overview 19
3.2 Stepwise review to each level markets 20
4. The Company 25
4.1 Vision and Mission 25
4.2 History 25
4.3 Location 26
4.4 Organization Structure 26
4.5 Products and Business Model 28
4.6 Shareholders 29
4.7 Bottleneck and Why IPO 29
5. The Industry 31
5.1 Evolution of Biotechnology Industry in Taiwan 31
5.2 Statistical Data of the Industry 32
5.3 H Company in the Industry 33
6. The Competitor 34
6.1 Medical Products 34
6.2 Cosmetics Products 34
6.3 Conclusions 38
7. The Customer 40
7.1 Target Customers and Needs 40
7.2 Fulfilments of Customer Needs 40
8. The Management 42
9. The Financials 45
9.1 Financial Positions 45
9.2 Income Performance 46
9.3 Pro-forma Financial Performance 49
9.4 Conclusion 59
10. The IPO Evaluation 62
10.1 IPO Evaluation 62
10.2 Plan 65
10.3 Conclusions 68
Reference 69
Appendix 70
1. Regulations from Taiwan Stock Exchange (http://www.twse.com.tw)
2. Regulations from Taipei Exchange (http://www.tpex.org.tw)
3. 2017生技產業白皮書 by經濟部生技醫藥產業發展推動小組(http://www.biopharm.org.tw)
4. 2017 中小企業白皮書 by 經濟部中小企業處
(http://www.moeasmea.gov.tw)
連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top